Lestat Ali

MD · Harvard

Residency · Internal Medicine Residencyalumni

ORCID 0000-0003-2673-1592

publications

first author

median RCR

2.42

citations

215

Publications

2025
Phase I study of ribociclib (CDK4/6 inhibitor) with spartalizumab (PD-1 inhibitor) with and without fulvestrant in metastatic hormone receptor-positive breast cancer or advanced ovarian cancer
Journal for ImmunoTherapy of Cancer
2024
Table S1 from PD-1 Blockade Induces Reactivation of Nonproductive T-Cell Responses Characterized by NF-κB Signaling in Patients with Pancreatic Cancer
2024
TCR raw data 2 from PD-1 Blockade Induces Reactivation of Nonproductive T-Cell Responses Characterized by NF-κB Signaling in Patients with Pancreatic Cancer
2024
Data from PD-1 Blockade Induces Reactivation of Nonproductive T-Cell Responses Characterized by NF-κB Signaling in Patients with Pancreatic Cancer
2024
PD-1 Blockade Induces Reactivation of Nonproductive T-Cell Responses Characterized by NF-κB Signaling in Patients with Pancreatic Cancer
Clinical Cancer Research
2024
Supplementary Data 1 from PD-1 Blockade Induces Reactivation of Nonproductive T-Cell Responses Characterized by NF-κB Signaling in Patients with Pancreatic Cancer
2024
Arm A count matrices 3 from PD-1 Blockade Induces Reactivation of Nonproductive T-Cell Responses Characterized by NF-κB Signaling in Patients with Pancreatic Cancer
2024
Arm B count matrices 4 from PD-1 Blockade Induces Reactivation of Nonproductive T-Cell Responses Characterized by NF-κB Signaling in Patients with Pancreatic Cancer
2023
PD-1 blockade and CDK4/6 inhibition augment nonoverlapping features of T cell activation in cancer
Journal of Experimental Medicine
2023
Supplemental Methods from Altered Binding of Tumor Antigenic Peptides to MHC Class I Affects CD8+ T Cell–Effector Responses
2023
Data from Altered Binding of Tumor Antigenic Peptides to MHC Class I Affects CD8+ T Cell–Effector Responses
2023
Data from Inhibition of CDK4/6 Promotes CD8 T-cell Memory Formation
2023
Supplementary Data from Inhibition of CDK4/6 Promotes CD8 T-cell Memory Formation
2023
cIAP1/2 Antagonism Induces Antigen-Specific T Cell–Dependent Immunity
The Journal of Immunology
2023
Table S2 from Inhibition of CDK4/6 Promotes CD8 T-cell Memory Formation
2023
Supplemental Data from Altered Binding of Tumor Antigenic Peptides to MHC Class I Affects CD8+ T Cell–Effector Responses
2021
Tissue eosinophils express the IL-33 receptor ST2 and type 2 cytokines in patients with eosinophilic esophagitis.
AllergyRCR 1.1614 citesPMID 34614218
2021
Replicability of neural responses to speech accent is driven by study design and analytical parameters
Scientific Reports
2021
cIAP1/2 antagonism eliminates MHC class I–negative tumors through T cell–dependent reprogramming of mononuclear phagocytes
Science Translational Medicine
2021
Inhibition of CDK4/6 Promotes CD8 T-cell Memory Formation
Cancer Discovery
2019
De novo design of potent and selective mimics of IL-2 and IL-15
Nature
2019
Transnuclear mice reveal Peyer's patch iNKT cells that regulate B‐cell class switching to IgG1
The EMBO Journal
2018
Anti-CTLA-4 therapy requires an Fc domain for efficacy.
Proceedings of the National Academy of Sciences of the United States of AmericaRCR 4.29127 citesPMID 29581255
2018
Targeting Cytokine Therapy to the Pancreatic Tumor Microenvironment Using PD-L1-Specific VHHs.
Cancer immunology researchRCR 2.4274 citesPMID 29459478
2018
Altered Binding of Tumor Antigenic Peptides to MHC Class I Affects CD8+ T Cell–Effector Responses
Cancer Immunology Research
2017
IAP Antagonists Enhance Cytokine Production from Mouse and Human iNKT Cells
Cancer Immunology Research
2017
Localized CD47 blockade enhances immunotherapy for murine melanoma
Proceedings of the National Academy of Sciences
2016
TRUSTED STATUS TRANSFER BETWEEN ASSOCIATED DEVICES
2015
SHARED DATA WITHIN A FAMILY

Compiled from public program rosters and open scholarly data (PubMed, OpenAlex, ORCID) with field-normalized impact (NIH iCite RCR). Publication attribution is being actively improved; counts shown are conservative.